274 related articles for article (PubMed ID: 17706532)
1. Normal and abnormal patterns of 18F-fluorodeoxyglucose PET/CT in lymphoma.
Bar-Shalom R
Radiol Clin North Am; 2007 Jul; 45(4):677-88, vi-vii. PubMed ID: 17706532
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of [18F]-FDG-Based Hybrid Imaging Combinations for Assessment of Bone Marrow Involvement in Lymphoma at Initial Staging.
Asenbaum U; Nolz R; Karanikas G; Furtner J; Woitek R; Staudenherz A; Senn D; Raderer M; Weber M; Simonitsch-Klupp I; Mayerhoefer ME
PLoS One; 2016; 11(10):e0164118. PubMed ID: 27723817
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma.
Mikosch P; Gallowitsch HJ; Zinke-Cerwenka W; Heinisch M; Pipam W; Eibl M; Kresnik E; Unterweger O; Linkesch W; Lind P
Acta Med Austriaca; 2003; 30(2):41-7. PubMed ID: 12752087
[TBL] [Abstract][Full Text] [Related]
5. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
6. PET/computed tomography and lymphoma.
Allen-Auerbach M; de Vos S; Czernin J
Radiol Clin North Am; 2013 Sep; 51(5):833-44. PubMed ID: 24010908
[TBL] [Abstract][Full Text] [Related]
7. The role of FDG-PET imaging in the management of lymphoma.
Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
[TBL] [Abstract][Full Text] [Related]
8. [Positron emission tomography (PET) with [18F]-FDG in bronchopulmonary cancer and its impact on medical decision at the time of diagnosis, staging, or recurrence evaluation].
Grahek D; Montravers F; Mayaud C; Regnard JF; Kerrou K; Younsi N; Talbot JN
Rev Pneumol Clin; 2001 Dec; 57(6):393-403. PubMed ID: 11924148
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
10. PET and PET/CT in management of the lymphomas.
Podoloff DA; Macapinlac HA
Radiol Clin North Am; 2007 Jul; 45(4):689-96, vii. PubMed ID: 17706533
[TBL] [Abstract][Full Text] [Related]
11. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
Kumar R; Xiu Y; Zhuang HM; Alavi A
Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
[TBL] [Abstract][Full Text] [Related]
12. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
[TBL] [Abstract][Full Text] [Related]
13. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
[TBL] [Abstract][Full Text] [Related]
14. Spectrum of (18)F-FDG PET/CT appearances in peritoneal disease.
Anthony MP; Khong PL; Zhang J
AJR Am J Roentgenol; 2009 Dec; 193(6):W523-9. PubMed ID: 19933627
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 18F-FDG Pet/CT and CT: diagnosis performance in lymphoma patient after treatment.
Chiewvit S; Thephamongkhol K; Ubolnuch K; Pooliam J; Phongsawat N; Chiewvit P
J Med Assoc Thai; 2014 Jan; 97(1):85-94. PubMed ID: 24701734
[TBL] [Abstract][Full Text] [Related]
16. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
17. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma.
Rini JN; Leonidas JC; Tomas MB; Palestro CJ
J Nucl Med; 2003 Jul; 44(7):1072-4. PubMed ID: 12843223
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Yield of Body CT and Whole-Body FDG PET/CT for Initial Systemic Staging in Patients With Suspected Primary CNS Lymphoma: A Systematic Review and Meta-Analysis.
Park HY; Suh CH; Huang RY; Guenette JP; Kim HS
AJR Am J Roentgenol; 2021 May; 216(5):1172-1182. PubMed ID: 32812800
[No Abstract] [Full Text] [Related]
[Next] [New Search]
